Clinical Trials Logo

Metastatic Lung Cancer clinical trials

View clinical trials related to Metastatic Lung Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05241873 Active, not recruiting - Neoplasms Clinical Trials

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Start date: March 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

NCT ID: NCT03867175 Active, not recruiting - Clinical trials for Metastatic Lung Cancer

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Start date: June 24, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies immunotherapy and stereotactic body radiation therapy to see how well it works compared with immunotherapy alone after first-line systemic therapy (therapy that goes throughout the body) in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving immunotherapy with stereotactic body radiation therapy may work better than immunotherapy alone in treating patients with non-small cell lung cancer.

NCT ID: NCT03177291 Active, not recruiting - Lung Cancer Clinical Trials

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Start date: September 26, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and non-small cell lung cancer (NSCLC). The investigational drug Pirfenidone is being combined with standard chemotherapy in participants with advanced non-small cell lung cancer. Pirfenidone is approved to treat idiopathic pulmonary fibrosis (IPF) but it isn't currently approved to treat non-small cell lung cancer.

NCT ID: NCT00986661 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Start date: October 2009
Phase: Phase 1
Study type: Interventional

This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.